Did you know that lawyers are now interested in screening and filing cases related to the adverse bleeding events in patients on the anti-coagulant drug Xarelto? Xarelto is a blood thinning drug manufactured and marketed through a joint venture between Bayer and Janssen Pharmaceuticals. Doctors prescribed this drug to patients that suffer from the heart condition Atrial Fibrillation (“A-Fib”) in order to help reduce the risks of developing a blood-clotting event like a stroke. If you know someone who has suffered injury as a result of an unexpected or uncontrolled bleeding event while on the drug Xarelto, they may have a legal case. The familes may have a wrongful death case on their hands.
The drug was also used post-operatively in patients undergoing major surgeries of the hip, knee or pelvis commonly associated with high risk of DVT or PE. In other cases, the drug is prescribed to patients who have suffered from deep vein thrombosis (DVT) or pulmonary embolism (PE) for prevention of a recurrence.
What is the main benefit advertised by the developers of Xarelto? Some claimed that Xarelto does not require periodic blood-work monitoring. Patients on Warfarin have their clotting abilities monitored through routine blood tests. Why are these tests done? These tests are a proactive effort to achieve an appropriate therapeutic level of the drug. The doctors want to watch for a sudden change in clotting abilities before dangerous clots form. Xarelto’s makers claim blood work monitoring is not required for their drug. What is the problem? No antidote exists to reverse the drugs’ effects.
Unlike Warfarin, we do not believe that there is a way to reverse the effects of Xarelto during a bleeding event or emergency. The developers of Xarelto should disclosed this information. What are the options left?
– Article by Richard Weaver, a Texas personal injury attorney with experience in pharmaceutical product liability cases.